<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411877</url>
  </required_header>
  <id_info>
    <org_study_id>RECCLAIM II-S</org_study_id>
    <nct_id>NCT02411877</nct_id>
  </id_info>
  <brief_title>REperfusion With Cooling in CerebraL Acute IscheMia II</brief_title>
  <acronym>RECCLAIM-II</acronym>
  <official_title>REperfusion With Cooling in CerebraL Acute IscheMia II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WellStar Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zoll Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>WellStar Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether reducing a patient's body temperature (mild&#xD;
      hypothermia of 33 degrees Centigrade) will significantly reduce the risk of brain injury&#xD;
      (notably reperfusion injury and hemorrhagic conversion) in patients who have suffered a&#xD;
      significant interruption of blood flow to an area of brain (occlusion of large proximal&#xD;
      cerebral artery) and have undergone successful removal of that interruption&#xD;
      (revascularization).This will be achieved by comparing patients who have undergone&#xD;
      hypothermia to those who have not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the safety and proof of concept of therapeutic hypothermia&#xD;
      prior to conventional revascularization in subjects experiencing acute ischemic stroke by&#xD;
      comparing the results to subjects who remain at normal body temperature (normothermic) and&#xD;
      proceed directly to reperfusion via conventional reperfusion intervention.&#xD;
&#xD;
      The investigational plan also examines the following outcomes in 85 subjects randomized to&#xD;
      either hypothermia or normothermia:&#xD;
&#xD;
        -  Regulation of biomarkers indicative of ischemia-reperfusion injury&#xD;
&#xD;
        -  Changes in blood brain injury using the Hyperintense Acute Reperfusion Marker (HARM)&#xD;
           protocol MRI as a surrogate imaging biomarker&#xD;
&#xD;
        -  Incidence of hemorrhagic conversion post reperfusion&#xD;
&#xD;
        -  Neurologic function at 90 days post acute ischemic stroke.&#xD;
&#xD;
      The results of this study will be used to power a definitive phase III clinical trial&#xD;
      evaluating the combination of hypothermia and revascularization versus reperfusion alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    It was decided that it was not feasible to continue this study.&#xD;
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemorrhagic Conversion</measure>
    <time_frame>48 hours</time_frame>
    <description>Acute bleeding into the area of the original stroke based on CT or MRI of the head.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperintense Acute Reperfusion Marker (HARM)</measure>
    <time_frame>48 +/- 24 hours</time_frame>
    <description>HARM is a MRI sequence looking at gadolinium enhancement on FLAIR MRI imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Baseline, 24 +/- 6 hours, 48 +/- 24 hours, 8 +/- 2 days, 90 +/- 15 days</time_frame>
    <description>NIHSS is a scale from 1-42 to evaluate stroke severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>Basline, 48 +/- 24 hours, 90 +/- 15 days</time_frame>
    <description>mRS is a straightforward evaluation of the functional limitations from stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluation and determination of the following complications pneumonias, central line infections, intra-cerebral hemorrhages, systemic hemorrhages, transient cerebral ischemia, and new strokes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normothermia</intervention_name>
    <description>Device: Trevo Pro Retriever (Stryker Corp.)</description>
    <arm_group_label>Normothermia</arm_group_label>
    <other_name>Clot retrieval, reperfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mild hypothermia</intervention_name>
    <description>Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)</description>
    <arm_group_label>Mild hypothermia</arm_group_label>
    <other_name>Therapeutic hypothermia, clot retrieval, reperfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trevo Pro Retriever (Stryker Corp.)</intervention_name>
    <description>Device: Trevo Pro Retriever (Stryker Corp.)</description>
    <arm_group_label>Mild hypothermia</arm_group_label>
    <arm_group_label>Normothermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zoll Thermogard XP technology with the Quattro catheter</intervention_name>
    <description>Device: Zoll Thermogard XP technology with the Quattro catheter</description>
    <arm_group_label>Mild hypothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects of any ethnicity and age &gt;/=18 but &lt;/= 79 years;&#xD;
&#xD;
          -  Symptom onset &lt;/=8 hours;&#xD;
&#xD;
          -  Symptoms consistent with an ischemic stroke with a large vessel occlusion (Middle&#xD;
             Cerebral Artery (MCA), Internal Carotid Artery (ICA) terminus) as determined by CT&#xD;
             imaging of the brain;&#xD;
&#xD;
          -  Alberta Stroke Program Early CT Score (ASPECTS) of 5-10 on non-contrast CT of the&#xD;
             brain;&#xD;
&#xD;
          -  Ability to undergo endovascular reperfusion therapy;&#xD;
&#xD;
          -  No contraindications to general anesthesia, conscious sedation, or allergies to any&#xD;
             components associated with the anticipated diagnostic or treatment procedures that&#xD;
             cannot be treated;&#xD;
&#xD;
          -  A pre-treatment modified Rankin Scale (mRS) of 0 or 1;&#xD;
&#xD;
          -  Baseline CT scan shows no hemorrhage;&#xD;
&#xD;
          -  National Institutes of Health Stroke Scale (NIHSS) 14-29;&#xD;
&#xD;
          -  Subject has either 1) failed iv tissue plasminogen activator (tPA) therapy or 2)&#xD;
             contradicted for iv tPA therapy;&#xD;
&#xD;
          -  Subject is capable of complying with study procedures and agrees to complete all&#xD;
             required study procedures, study visits and associated activities.&#xD;
&#xD;
          -  Subject or legally authorized representative must be able to understand and give&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant or not using adequate&#xD;
             contraception;&#xD;
&#xD;
          -  Bleeding diathesis with a platelet count &lt; 50,000 or International Normalized Ratio&#xD;
             (INR) &gt;1.7 or any active or recent (within 10 to 30 days) hemorrhage;&#xD;
&#xD;
          -  History of genetically confirmed hypercoagulable syndrome;&#xD;
&#xD;
          -  Any condition that excludes MRI imaging;&#xD;
&#xD;
          -  History of dementia, currently on Aricept or Namenda, or other Alzheimer's-like&#xD;
             symptoms;&#xD;
&#xD;
          -  End stage renal disease on hemodialysis;&#xD;
&#xD;
          -  History of cardiac arrest;&#xD;
&#xD;
          -  Presence of an inferior vena cava (IVC) filter;&#xD;
&#xD;
          -  Contrast dye allergy with history of anaphylaxis, known serious sensitivity to&#xD;
             contrast agents or any condition in which angiography is contraindicated;&#xD;
&#xD;
          -  Known allergy to meperidine or buspar;&#xD;
&#xD;
          -  Prior neurologic event that would obscure interpretation of the signal and current&#xD;
             presenting neurologic deficits;&#xD;
&#xD;
          -  Sustained hypertension (systolic blood pressure (SBP) &gt; 185 or diastolic blood&#xD;
             pressure (DBP) &gt; 110 refractory to treatment);&#xD;
&#xD;
          -  Baseline CT/MRI of head showing evidence of mass effect with mid-line shift,&#xD;
             hemorrhage, intracranial tumor, arterial vasculitis or dissection, or bilateral&#xD;
             stroke;&#xD;
&#xD;
          -  Presence of any other serious comorbidity that would be likely to impact life&#xD;
             expectancy to less than 6 months or limit subject cooperation or study compliance;&#xD;
&#xD;
          -  Concurrent participation in an investigational clinical study that has not completed&#xD;
             the follow-up period or planned participation in another study within the next 3&#xD;
             months;&#xD;
&#xD;
          -  Any other condition or personal circumstance that, in the judgment of the&#xD;
             investigator, might interfere with the collection of complete, good quality data or&#xD;
             the completion of the research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi Gupta, MD</last_name>
    <role>Study Director</role>
    <affiliation>WellStar Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WellStar Kennestone Regional Medical Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Mild hypothermia</keyword>
  <keyword>Stroke</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Cerebral infarction</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Cerebrovascular disorder</keyword>
  <keyword>Brain disease</keyword>
  <keyword>Central nervous system disease</keyword>
  <keyword>Nervous system disease</keyword>
  <keyword>Vascular disease</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Brain infarction</keyword>
  <keyword>Brain ischemia</keyword>
  <keyword>Pathologic process</keyword>
  <keyword>Body temperature change</keyword>
  <keyword>Signs and symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

